Skip to content

Theravance Biopharma TBPH Total Cost of Revenue

Discontinued — last reported Q4 '17

Total Cost of Revenue at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.9M+41.0%
LQD
Liquidia CorporationLQDA
$1.52M+3.4%
United Therapeutics logo
United TherapeuticsUTHR
$133.4M+44.2%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$6.51M-24.1%
Precigen logo
PrecigenPGEN
$10.64M+20.1%
Organon logo
OrganonOGN
$677M+0.7%

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$890.32M+67.5%
Enterprise value$642.72M+37.0%
P/E7.8×
P/S8.1×0.0×

Profitability

See full
Gross margin60.8%
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsSold.

The official record: Theravance Biopharma’s 10-K, filed February 28, 2018, on SEC EDGAR. View the filing →

Questions, answered.

What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.